Tscan therapeutics expands manufacturing leadership with the appointment of justin mccue, ph.d., as chief technology officer

Waltham, mass., dec. 04, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of justin mccue, ph.d., as its chief technology officer. dr. mccue joins tscan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of t cell therapy products.
TCRX Ratings Summary
TCRX Quant Ranking